A discovery study to identify clinical and genetic risk factors for bevacizumab (BEV)-related gastrointestinal (GI) hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated on CALGB 90401 (Alliance)
- Citation:
- Cancer Res vol 76 (14 suppl) abstr 2037
- Meeting Instance:
- AACR 2016
- Year:
- 2016
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3894
- Pharmas:
- Genentech
- Grants:
- U10CA180821
- Corr. Author:
- Authors:
- Jai N. Patel Chen Jiang Kouros Owzar Daniel L. Hertz Flora A. Mulkey William K. Kelly Susan Halabi Yoichi Furukawa Cameron Lassiter Susan G. Dorsey Paula N. Friedman Eric J. Small Phillip G. Febbo Deanna L. Kroetz Michael A. Carducci John F. Mahoney Michael J. Kelley Yusuke Nakamura Michiaki Kubo Mark J. Ratain Michael J. Morris Howard L. McLeod
- Networks:
- CA136, LAPS-IL036, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-NC007, LAPS-NY016, NC002
- Study
- CALGB-90401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: